Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-22 19:31 CEST (UTC+2h)

long half life drug bioequivalence study design [Design Issues]

posted by ElMaestro - Denmark, 2017-08-16 12:53  - Posting: # 17691
Views: 2,610

Hi ssussu,

» Should I just need to design the sampling time to 72hr or need to longer than 72hr?
» If I just sampling for 72hr, how can I prove the drug is a long half life drug?

In my humble opinion and experience:It is not much of a deal, actually.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,418 posts in 3,912 threads, 1,173 registered users;
online 17 (0 registered, 17 guests [including 8 identified bots]).

The greatest shortcoming of the human race is our inability
to understand the exponential function.    Albert Bartlett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed